NASDAQ · AKTX
Akari Therapeutics plc ADS
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AKTX: Nov 12, 2026
Akari Therapeutics plc ADS is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $0.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews- RTTNews · Oct 15, 12:11 PM EDTAkari Therapeutics Seeks To Address ADC Resistance With Novel PH1 Payload; Stock Up(RTTNews) – Akari Therapeutics Plc (AKTX), an oncology biotechnology company, outlined its differentiated antibody-drug conjugate (ADC) payload strategy and development priorities in a new CEO Corner segment featuring President and CEO Abizer Gaslightwala.
- RTTNews · Oct 1, 11:26 AM EDTAkari Expands IP Portfolio With PCT Filing For PH1 ADC Payload(RTTNews) – On Thursday, Akari Therapeutics (AKTX) said it filed a new PCT application covering its PH1 payload and its ability to disrupt multiple cancer-driving pathways through RNA splicing modulation.
- RTTNews · Aug 29, 6:34 AM EDTWhy Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories(RTTNews) – The Virtual Investor "Why Now" On-Demand Conference, hosted by Virtual Investor Co. in partnership with JTC Team, wrapped up on August 27, 2026. The program is designed to give investors and analysts direct access to management teams, each presenting why now is the ri
- RTTNews · Aug 18, 11:35 AM EDTAkari Reports Preclinical Activity For AKTX-101 In Urothelial Cancer Model(RTTNews) – Akari Therapeutics, Plc (AKTX), an oncology biotech company developing antibody-drug conjugates (ADCs) with novel RNA splicing modulator payloads, on Tuesday announced new preclinical data for AKTX-101.
- RTTNews · Jul 21, 10:35 AM EDTAkari Enters Strategic Research Collaboration With Whitehawk To Advance ADC Innovation; Stock Down(RTTNews) – Akari Therapeutics, Plc. (AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs announced a strategic research collaboration with Whitehawk Therapeutics, Inc. (WHWK), a clinical-stage oncology therapeutics company, to advance ADC innovatio
- RTTNews · Jul 21, 10:24 AM EDTAkari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics, Stock Down(RTTNews) – Akari Therapeutics, Plc (AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with Whitehawk Therapeutics, a clinical-stage oncology therapeut
- RTTNews · May 29, 2:27 AM EDTTop Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest(RTTNews) – In Thursday's list of gainers, we highlight SciSparc, which received the regulatory go-ahead to acquire a stake in a private Israeli technology company, Co-Diagnostics, which extended its rally for the third straight day, and Tevogen, which is making continued progres
- RTTNews · May 26, 3:50 AM EDTTop Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watch(RTTNews) – Biotech stocks witnessed strong momentum on Friday, with Akari Therapeutics leading the pack, driven by encouraging preclinical pancreatic cancer data for AKTX-101. MetaVia, GeoVax, Polyrizon, and Sol-Gel were also some of the companies that captured Wall Street's at
- RTTNews · May 22, 5:31 AM EDTAkari Shares Surge In Pre-Market On Breakthrough Data Showing Synergy KRAS Inhibition(RTTNews) – Shares of Akari Therapeutics, Plc (AKTX) are up over 100% in pre-market trading after the company reported breakthrough preclinical data demonstrating that its lead antibody-drug conjugate, AKTX-101, works synergistically with a KRAS inhibitor in KRAS-mutated pancreat
- RTTNews · May 21, 10:34 PM EDTBiotech Stock Gainers: CODX Extends Rally, SBFM Surges, GOVX Ebola Strategy, RGNX Awaits Catalysts(RTTNews) – Today's gainers include CODX, which rallied for the third straight day; Akari, on breakthrough clinical data in pancreatic cancer; Sunshine, following regulatory approval for its generic Amoxicillin; GOVX, amid Ebola concerns; and RGNX, on upcoming clinical trial mile
- RTTNews · May 21, 9:55 AM EDTAkari Therapeutics Prices $5.5 Mln Private Placement To Advance AKTX-10; Stock Down(RTTNews) – Akari Therapeutics, Plc (AKTX), an oncology biotechnology company, announced the pricing of a private placement for gross proceeds of approximately $5.5 million. The firm entered into definitive purchase agreements with the investors for the issuance and sale of 1.47
- RTTNews · Apr 21, 4:42 AM EDTAkari Presents Positive Preclinical Data For AKTX-101(RTTNews) – Akari Therapeutics Plc (AKTX), an oncology biotechnology company, on Monday presented positive preclinical data for AKTX-101, a developing antibody-drug conjugate targeting various cancer indications, at the 2026 annual meeting of the American Association of Cancer Re
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Akari Therapeutics plc ADS from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.